Astrocytoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major astrocytoma markets are expected to exhibit a CAGR of 4.4% during 2024-2034.
The astrocytoma market has been comprehensively analyzed in IMARC's new report titled "Astrocytoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Astrocytoma refers to a type of brain tumor that originates from astrocytes, which are a form of glial cell present in the central nervous system. Glial cells provide support and nourishment to neurons and play various roles in maintaining the normal functioning of the brain. Some of the common symptoms associated with the ailment include persistent headaches, seizures, changes in cognitive function, personality or behavior alterations, weakness or numbness in limbs, difficulty with balance and coordination, vision or hearing problems, speech difficulties, etc. The diagnosis of astrocytoma involves a comprehensive evaluation by medical professionals. It typically includes a combination of imaging studies, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, which help in visualizing the brain and identifying the presence of a tumor. In some cases, a biopsy is necessary to obtain a sample of the tumor tissue for microscopic examination to determine the tumor type and grade. Various other diagnostic tests, including neurological studies and cognitive assessments, may also be conducted to evaluate the patient's overall brain function and identify any specific deficits or abnormalities associated with the tumor.
The escalating incidence of genetic mutations that lead to alterations in cellular metabolism and contribute to tumor development and progression is primarily driving the astrocytoma market. In addition to this, the rising cases of exposure to high levels of ionizing radiation, such as radiation therapy for other medical conditions or occupational exposure in certain industries, which cause damage at the cellular level, are also creating a positive outlook for the market. Moreover, the widespread adoption of proton therapy that delivers higher doses of radiation to the tumor while minimizing damage to the surrounding healthy tissues is further bolstering the market growth. Apart from this, the inflating application of targeted therapy to selectively inhibit specific molecules or signaling pathways involved in tumor growth and progression is also acting as another significant growth-inducing factor. Additionally, the ongoing advancements in surgical techniques, such as the introduction of awake craniotomy, intraoperative MRI, fluorescence-guided surgery, neuronavigation systems, etc., which aid surgeons in achieving maximal tumor removal and preserving neurological function, are expected to drive the astrocytoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the astrocytoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for astrocytoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the astrocytoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the astrocytoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the astrocytoma market
Reimbursement scenario in the market
In-market and pipeline drugs
This report also provides a detailed analysis of the current astrocytoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the astrocytoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the astrocytoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the astrocytoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of astrocytoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of astrocytoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of astrocytoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with astrocytoma across the seven major markets?
What is the size of the astrocytoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of astrocytoma?
What will be the growth rate of patients across the seven major markets?
Astrocytoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for astrocytoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the astrocytoma market?
What are the key regulatory events related to the astrocytoma market?
What is the structure of clinical trial landscape by status related to the astrocytoma market?
What is the structure of clinical trial landscape by phase related to the astrocytoma market?
What is the structure of clinical trial landscape by route of administration related to the astrocytoma market?
The astrocytoma market has been comprehensively analyzed in IMARC's new report titled "Astrocytoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Astrocytoma refers to a type of brain tumor that originates from astrocytes, which are a form of glial cell present in the central nervous system. Glial cells provide support and nourishment to neurons and play various roles in maintaining the normal functioning of the brain. Some of the common symptoms associated with the ailment include persistent headaches, seizures, changes in cognitive function, personality or behavior alterations, weakness or numbness in limbs, difficulty with balance and coordination, vision or hearing problems, speech difficulties, etc. The diagnosis of astrocytoma involves a comprehensive evaluation by medical professionals. It typically includes a combination of imaging studies, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, which help in visualizing the brain and identifying the presence of a tumor. In some cases, a biopsy is necessary to obtain a sample of the tumor tissue for microscopic examination to determine the tumor type and grade. Various other diagnostic tests, including neurological studies and cognitive assessments, may also be conducted to evaluate the patient's overall brain function and identify any specific deficits or abnormalities associated with the tumor.
The escalating incidence of genetic mutations that lead to alterations in cellular metabolism and contribute to tumor development and progression is primarily driving the astrocytoma market. In addition to this, the rising cases of exposure to high levels of ionizing radiation, such as radiation therapy for other medical conditions or occupational exposure in certain industries, which cause damage at the cellular level, are also creating a positive outlook for the market. Moreover, the widespread adoption of proton therapy that delivers higher doses of radiation to the tumor while minimizing damage to the surrounding healthy tissues is further bolstering the market growth. Apart from this, the inflating application of targeted therapy to selectively inhibit specific molecules or signaling pathways involved in tumor growth and progression is also acting as another significant growth-inducing factor. Additionally, the ongoing advancements in surgical techniques, such as the introduction of awake craniotomy, intraoperative MRI, fluorescence-guided surgery, neuronavigation systems, etc., which aid surgeons in achieving maximal tumor removal and preserving neurological function, are expected to drive the astrocytoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the astrocytoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for astrocytoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the astrocytoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the astrocytoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the astrocytoma market
Reimbursement scenario in the market
In-market and pipeline drugs
This report also provides a detailed analysis of the current astrocytoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the astrocytoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the astrocytoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the astrocytoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of astrocytoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of astrocytoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of astrocytoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with astrocytoma across the seven major markets?
What is the size of the astrocytoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of astrocytoma?
What will be the growth rate of patients across the seven major markets?
Astrocytoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for astrocytoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the astrocytoma market?
What are the key regulatory events related to the astrocytoma market?
What is the structure of clinical trial landscape by status related to the astrocytoma market?
What is the structure of clinical trial landscape by phase related to the astrocytoma market?
What is the structure of clinical trial landscape by route of administration related to the astrocytoma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ASTROCYTOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ASTROCYTOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ASTROCYTOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ASTROCYTOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ASTROCYTOMA - UNMET NEEDS
10 ASTROCYTOMA - KEY ENDPOINTS OF TREATMENT
11 ASTROCYTOMA - MARKETED PRODUCTS
11.1 List of Astrocytoma Marketed Drugs Across the Top 7 Markets
11.1.1 BiCNU (carmustine) - Heritage Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Temodar (Temozolomide) - Merck & Co
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Avastin (Bevacizumab) - Genentech/Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ASTROCYTOMA - PIPELINE DRUGS
12.1 List of Astrocytoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Vorasidenib+Pembrolizumab - Servier
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Debio 0123 - Debiopharm International
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 MDNA55 - Medicenna Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 OKN-007 - Oblato
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Retifanlimab - Incyte Corporation
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ASTROCYTOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ASTROCYTOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ASTROCYTOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Astrocytoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Astrocytoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Astrocytoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Astrocytoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Astrocytoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Astrocytoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Astrocytoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Astrocytoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Astrocytoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Astrocytoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Astrocytoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Astrocytoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Astrocytoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Astrocytoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Astrocytoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Astrocytoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Astrocytoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Astrocytoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Astrocytoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Astrocytoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Astrocytoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Astrocytoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Astrocytoma - Access and Reimbursement Overview
16 ASTROCYTOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ASTROCYTOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ASTROCYTOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ASTROCYTOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ASTROCYTOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ASTROCYTOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ASTROCYTOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ASTROCYTOMA - UNMET NEEDS
10 ASTROCYTOMA - KEY ENDPOINTS OF TREATMENT
11 ASTROCYTOMA - MARKETED PRODUCTS
11.1 List of Astrocytoma Marketed Drugs Across the Top 7 Markets
11.1.1 BiCNU (carmustine) - Heritage Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Temodar (Temozolomide) - Merck & Co
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Avastin (Bevacizumab) - Genentech/Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ASTROCYTOMA - PIPELINE DRUGS
12.1 List of Astrocytoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Vorasidenib+Pembrolizumab - Servier
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Debio 0123 - Debiopharm International
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 MDNA55 - Medicenna Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 OKN-007 - Oblato
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Retifanlimab - Incyte Corporation
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ASTROCYTOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ASTROCYTOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ASTROCYTOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Astrocytoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Astrocytoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Astrocytoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Astrocytoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Astrocytoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Astrocytoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Astrocytoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Astrocytoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Astrocytoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Astrocytoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Astrocytoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Astrocytoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Astrocytoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Astrocytoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Astrocytoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Astrocytoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Astrocytoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Astrocytoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Astrocytoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Astrocytoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Astrocytoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Astrocytoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Astrocytoma - Access and Reimbursement Overview
16 ASTROCYTOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ASTROCYTOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ASTROCYTOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
